ERBB2 and invasive breast carcinoma: In this regard, Singer et al. performed the phase II, ABCSG trial (EudraCT#2011-004822-85) to evaluate the addition of tecemotide to SoC, neoadjuvant chemotherapy in HER2-negative, early invasive breast cancer patients.